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Objective. The etiology of oral verrucous carcinoma is unknown, and human papillomavirus ‘involvement’ remains
contentious. The uncertainty can be attributed to varied detection procedures and difficulties in defining ‘gold-standard’
histologic criteria for diagnosing ‘verrucous’ lesions. Their paucity also hampers investigation. We aimed to analyze oral
verrucous lesions for human papillomavirus (HPV) subtype genomes.
Study Design. We used next-generation sequencing for the detection of papillomavirus sequences, identifying subtypes and
computing viral loads. We identified a total of 78 oral verrucous cases (62 carcinomas and 16 hyperplasias). DNA was
extracted from all and sequenced at a coverage between 2.5% and 13%.
Results. An HPV-16 sequence was detected in 1 carcinoma and 1 hyperplasia, and an HPV-2 sequence was detected in 1
carcinoma out of the 78 cases, with viral loads of 2.24, 8.16, and 0.33 viral genomes per cell, respectively.
Conclusions. Our results indicate no conclusive human papillomavirus involvement in oral verrucous carcinoma or
hyperplasia. (Oral Surg Oral Med Oral Pathol Oral Radiol 2014;118:117-125)Head and neck squamous cell carcinoma (HNSCC) is
the sixth most common cancer in the world, with an
incidence of about 600 000 cases each year and a 5-year
survival rate of only about 50%.1 Around half of these
cases occur in the oral cavity.2 Most cases represent
oral squamous cell carcinoma (OSCC), which is found
mainly in older men exposed to tobacco and alcohol.3
Verrucous carcinoma (VC) is a low-grade variant of*Joint ﬁrst authors.
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with distant metastasis.4
The association between human papillomavirus
(HPV) and HNSCC is strongest among oropharyngeal
squamous cell carcinomas (OPSCC), especially for
cancers of the lingual and palatine tonsils.5-9 Further-
more, the risk of developing oropharyngeal cancer
when adjusted for tobacco and alcohol use is substan-
tially increased with high-risk HPV oral infections.9
HPV has been identiﬁed in 45% to 95% of OPSCC10-12
and is believed to be an etiologic agent.13 In 2012,
Kansy et al.14 conducted a systematic review encom-
passing 5338 patients to assess the role of high-risk
HPV types in OSCC, and 30.1% revealed HPV-positive
OSCC samples. Within this review, HPV type 16 was
identiﬁed in 25.4% and type 18 in 18.1%. However, the
role of HPV as a causative factor was not well deﬁned.
In general, HPV-positive carcinomas have better
prognosis and treatment response than HPV-nega-
tives.13,15,16 Studies ﬁnd a 2- to 3-year overall survivalStatement of Clinical Relevance
We found that oral verrucous carcinomas and hy-
perplasias are rarely associated with human papil-
lomavirus infection. Our next-generation sequencing
methodology allowed us to test for all human vi-
ruses. We conclude that papillomavirus infections
are not involved in the development of these tumors.
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Fig. 1. A, Photomicrograph of oral verrucous carcinoma showing ‘extension’ into underlying mucous salivary glands. It ‘retains’
the bulbous rete seen in verrucous hyperplasia, but clearly has a ‘pushing’ advancing front that now extends considerably deeper
than adjacent normal epithelium (hematoxylin-eosin, original magniﬁcation approximately  100). B, A higher-power view of the
deep margin from panel A. Note the lack of nuclear pleomorphism (hematoxylin-eosin, original magniﬁcation
approximately  400). C, Photomicrograph of p16INK4a immunohistochemical staining of the only HPV16-positive, tongue-based
OVC identiﬁed by NGS. A majority of the nuclei are showing strong positive staining (original magniﬁcation
approximately  250) (antibody F-12: sc-1661; Santa Cruz Biotechnology Inc; using high-pH range settings on Dako Autostainer
Link 48; Ely, United Kingdom). (HPV, human papillomavirus; OVC, oral verrucous carcinoma; NGS, next-generation sequencing.)
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compared with about 85% for HPV-positives,15,16
indicating the importance of accurate HPV detection
and subtyping.
Oral verrucous carcinoma (OVC) accounts for 2% to
10% of all OSCC cases.17 ‘Verrucous’ terminology is
applied to lesions that show exophytic, keratotic sur-
faces made of blunt or sharp epithelial projections, ﬁl-
led with keratin invaginations, but without clear
ﬁbrovascular cores.18 Histologically, OVC consists of
thickened, club-shaped papillae and blunt stromal in-
vaginations of well-differentiated squamous epithelium
with marked keratinization (Figure 1, A, B), with the
squamous epithelium lacking cytologic criteria of ma-
lignancy. OVC invades underlying stroma with a
pushing, rather than inﬁltrating, front.19 Oral verrucous
hyperplasia (OVH) (Figure 2) and proliferative verru-
cous leukoplakia are both poorly deﬁned but are
believed to be histologic precursors of OVC and
possibly OSCC.20,21 Because a verrucous appearance
suggests a viral etiology, this has prompted a number of
investigations for HPV.22,23 Patel et al.24 recently
concluded that verrucous carcinomas of the head and
neck lacked transcriptionally active high-risk human
papillomavirus, but they concluded with “our study
numbers, although relatively generous for a tumor asrare as verrucous carcinoma, are still relatively small
and may not reﬂect results on larger cohorts of these
tumors.”
Most studies (Table I)23,25-31 relied on polymerase
chain reaction (PCR) or in situ hybridization for
detection and did not identify HPV transcriptional
activity markers, did not quantitate HPV viral load, or
relied on a low sample number. Koskinen et al.32 re-
ported that 37 of 61 (61%) head and neck cancer
samples were positive for HPV and that HPV-16 was
the most frequently detected type (31 of 37, 84%).
The aim of this study was to analyze a large cohort of
oral verrucous lesions for the presence of HPV sub-
types, as well as any other viral genomes, using next-
generation sequencing (NGS). The cohort included VC
and VH but excluded so-called hybrid lesions where
VC and inﬁltrative SCC exist,19 as well as lesions with
distant metastases, as these lesions are not representa-
tive of ‘classical’ VC.
MATERIALS AND METHODS
Sample selection
Of the samples included, 28 were collected from the
Pathology Department, St James’s University Hospital,
Leeds, United Kingdom; 16 from the Pathology Divi-
sion, Queen Victoria Hospital, East Grinstead, United
Fig. 2. A, B, Photomicrograph of oral verrucous hyperplasia showing markedly acanthotic epithelium, with bulbous, club-shaped
papillae lacking signiﬁcant cellular atypia (A), adjacent to more normal epithelium (B) (A, B, hematoxylin-eosin, original
magniﬁcation approximately  250). In comparison with Figure 1, the affected epithelium does not show any signiﬁcant ‘deep
extension.’
Table I. Previous studies of HPV detection in oral verrucous lesions
Author Year
Lesion
location Diagnosis
No. of
cases
No. of HPV-
positive lesions
HPV detection
method Identiﬁed HPV genotypes
Stokes et al.25 2012 Oral VC 7 1/7 ISH, PCR HPV-16
Dysplastic
verrucous
lesions
13 5/13
Adler-Storthz
et al.26
1986 Oral VC 9 3/9 ISH HPV-2
Noble-Topham
et al.27
1993 Oral VC 25 12/25 PCR HPV-6, 11, 16, 18
Shroyer et al.28 1993 Oral VC 17 7/17 PCR, ISH HPV-6, 11, 16, 18, 31, 33, 35
Balaram et al.29 1995 Oral VC 15 10/15 PCR HPV-6, 11, 16, 18
Mitsuishi et al.30 2005 Oral VC 4 4/4 PCR HPV-2, 18, 20, 27, 57, 62, and
partial sequences of an
unknown HPV type
Fujita et al.31 2008 Oral VC 23 11/23 PCR, ISH HPV-6, 11, 18, 33, 74
Del Pino et al.23 2012 Head and
neck
VC 5 1/5 PCR HPV-35, 45
Head and
neck
VH 1 0/1
HPV, human papillomavirus; VC, verrucous carcinoma; VH, verrucous hyperplasia; PCR, polymerase chain reaction; ISH, in situ hybridization.
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of Turin, Italy; and 8 from the Department of Pathol-
ogy, National Guard Hospital, Saudi Arabia. Written
informed consent and approval was obtained for all
patients for the use of their tissue in this research (Leeds
Research Ethics Committee reference 07/Q1206/30).
Verrucous-appearing, but clearly ‘invasive,’ squamous
lesions were classiﬁed as verrucous SCC and
excluded.19
DNA extraction
Seven 10-mm sections were cut from each block onto
plain glass slides. Premalignant or malignant areas were
microscopically identiﬁed and marked on a corre-
sponding hematoxylin-eosin-stained slide. Sections
were dewaxed and macrodissected with a sterile scalpel
blade to obtain >70% tumor cell content for DNAisolation, performed using Qiagen DNA extraction kits
(Qiagen, Sussex, United Kingdom), according to the
manufacturer’s instructions. DNA extraction was suc-
cessful in 78 cases.Determining DNA concentration and purity
Nucleic acid concentration and purity were measured
using the NanoDrop UV spectrophotometer NanoDrop-
8000 (Thermo Scientiﬁc, Wilmington, DE, USA). Be-
sides the concentration, A260:230 and A260:280 ratios
were obtained, which are used as indicators of the pu-
rity of the samples. Double-stranded DNA concentra-
tion was speciﬁcally quantiﬁed using the Quant-iT
PicoGreen dsDNA BR assay (Invitrogen, Paisley,
United Kingdom). Of 94 cases, 78 yielded sufﬁcient
DNA for library preparation and NGS analysis.
Table II. Summary of lesion types and patients
Type of lesion n Age Male Female
OVC 62 38-96 (mean ¼ 67.2) 33 32
OVH 16 52-80 (mean ¼ 67) 5 8
OVH, oral verrucous hyperplasia; OVC, oral verrucous carcinoma.
ORAL AND MAXILLOFACIAL PATHOLOGY OOOO
120 Samman et al. July 2014Library preparation and sequencing
Library preparation for Illumina Genome analyser
GAIIx sequencing. Brieﬂy, between 5 ng and 1 mg of
DNA was sheared on a Covaris S2 Sample Preparation
System (Covaris Inc, Woburn, MA, USA). Sheared
DNA samples were checked for appropriate size dis-
tribution according to the manufacturer’s instructions
on an Agilent Bioanalyser DNA 1000 LabChip (Agi-
lent Technologies Inc, Santa Clara, CA, USA). The
End-It DNA End-Repair Kit (Epicentre Bio-
technologies, Madison, WI, USA) was used to convert
DNA with damaged ends to blunt-ended, 50-phosphor-
ylated DNA. Klenow DNA polymerase was used to add
an A base to each blunt-ended DNA fragment so that
adapters could be ligated. Six base pairs (bp) of unique
oligonucleotide tag sequence (adapter) were ligated to
the ends of the DNA fragments using methods previ-
ously published.33 DNA fragments were size selected to
200 bp using magnetic beads. DNA was recovered
using QiaQuick gel extraction kit (Qiagen, Venlo,
Netherlands) standard protocols, after which a step
comprising 12 enrichment PCR cycles was performed.
DNA libraries were examined using Invitrogen’s
Quant-iT Picogreen dsDNA BR assay kit and Agilent
Bioanalyser DNA 1000 LabChip to assess DNA con-
centration and quality, respectively (Agilent Technol-
ogies Inc). Equimolar amounts of each DNA library
were pooled for cluster ampliﬁcation and multiplexed
up to 20 samples per lane for 76-bp Illumina single-end
sequencing, where each read includes 6 bp of tagged
adapter and 70 bp of genomic DNA sequence.
Library preparation for Illumina HiSeq 2000
sequencing. For sequencing using HiSeq 2000, DNA
libraries were prepared using NEBNext DNA Library
Prep Master mix as described for Illumina (New En-
gland BioLabs Inc, Hitchin, United Kingdom). Be-
tween 200 ng and 300 ng of DNA was sheared on a
Covaris S2 Sample Preparation System (Covaris Inc)
and checked for appropriate size distribution on an
Agilent TapeStation D1K High Sensitivity ScreenTape
(Agilent Technologies Inc). After puriﬁcation, DNA
fragments were end repaired to convert DNA contain-
ing damaged ends to blunt-ended, 50-phosphorylated
DNA according to the manufacturer’s instructions.
End-repaired DNA fragments were dA-tailed and
ligated with the NEBNext adaptor. Adaptor-ligated
DNA fragments were size selected to 200 bp using
magnetic beads (Agencourt AMPure; Beckman Coulter
Inc, Danvers, MA, USA). Adaptor-ligated DNA frag-
ments were tagged to 96 different indexed primers
designed by our group (Integrated DNA Technologies
Inc, Glasgow, United Kingdom) and PCR-enriched
using 15 enrichment PCR cycles. All reagents used,
with the exception of the indexed primers, were part ofthe NEBNext DNA Library Prep Master mix with a
NEB adaptor as described for Illumina. Libraries were
then examined using Invitrogen’s Quant-iT Picogreen
dsDNA BR assay kit and Agilent TapeStation D1K
High Sensitivity ScreenTape to assess DNA concen-
tration and quality, respectively (Agilent Technologies
Inc). Samples were pooled, up to 50 samples per lane,
and paired-end sequenced (2  100 bp) on an Illumina
HiSeq 2000.Data analysis
Alignment and sequencing. Reads were split into
separate ﬁles according to tag and aligned to the human
reference genome (University of California Santa Cruz
version GRCh37/hg19, http://genome.ucsc.edu) and
to all known viral genomes, including HPV subtypes,
downloaded from the National Center for Biotech-
nology Information (http://www.ncbi.nlm.nih.gov/
genomes/GenomesHome.cgi?taxid%20¼%2010239).
Human genomic copy number analysis. Human
DNA copy number analysis was calculated and
analyzed as recently described.34 Sample reads were
arranged and organized by chromosome and position.
The ratio of test to control reads was calculated across
the genome in equally sized windows, averaging 200
tumor reads. A control sample was pooled from a group
of 20 data sets for normal individuals downloaded from
the 1000 Genomes Project35 (ftp://ftp.1000genomes.
ebi.ac.uk/vol1/ftp).
Viral genomes, HPV subtype detection, and load
measurements by sequencing. Viral load was measured
as previously described by Conway et al.36 This tech-
nique has been found to have good sensitivity and
speciﬁcity, with the additional beneﬁts of providing
information on viral subtype and load but also
informing genomic copy number. The number of reads
aligning to the human genome was used to calculate
read depth, in terms of reads per Kb. (For example, 1
million human reads in a 6-Gb diploid human genome
equates to 1 read for every 6 Kb of human DNA.) Next,
the number of reads uniquely aligning to viral genomes
was counted. This was equated to a certain number of
Kb viral sequence per human genome and hence the
number of viral genomes per human genome. (For
example, if 5 HPV reads are detected, and we have
previously calculated that there is 1 read every 6 Kb,
then there is likely to be around 30 Kb of viral DNA per
OOOO ORIGINAL ARTICLE
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per cell.) We can also calculate the probability of
detecting 1 copy of the HPV genome per cell, as
follows:p ¼ 1 eð0ð7900bp viral genome  number of human readsÞ=6 billionbp diploid human genomeÞSo a sample with 1 million human reads has a 73%
chance of detecting a single copy of the HPV genome per
cell, whereas a sample with 3 million reads has a 98%
chance. Higher viral loads will be easier to detect. Given a
certain number of human reads, the possible viral load that
could be detected with 95% conﬁdence is as follows:
ð0 logð10:95Þ6MbdiploidhumangenomeÞ=
ð7:9Kbviral genomenumberof humanreadsÞ
So, for example, only 456 000 reads are needed to detect
a load of 5 viral copies per cell with 95% conﬁdence.
We used HPV sequencing data from a previous study
(from our group) that included positive and negative
controls.36 NGS in HPV-positive cases was compared
with the gold standard of p16 immunohistochemistry
(antibody F-12: Sc-1661; Santa Cruz Biotechnology
Inc) using high-pH range settings on Dako Autostainer
Link 48 (Ely, United Kingdom) and found to be com-
parable in sensitivity and speciﬁcity.
RESULTS
A total of 78 patients, including 41 women and 37 men
(mean age, 67 years; range, 38-96) were included
(Table II). Full data are given in Supplemental
Table S1, available at www.oooojournal.net. Tumor
DNA was extracted from a total of 94 samples, and 78
(83%) of these yielded sufﬁcient DNA for library
preparations and NGS. Neither the age of the formalin-
ﬁxed, parafﬁn-embedded block nor the amount of tissue
sampled correlated with low yields.HPV
Sequencing libraries were prepared from 78 samples.
Table III lists the range of human and viral reads. HPV-
16 sequence was identiﬁed in 1 OVH and 1 OVC, and
HPV-2 sequence was detected in 1 OVC out of 78
samples at 95% conﬁdence level with 2.24, 8.16, and
0.33 viral genomes per cell, respectively. The standard
deviation of reads taken from all samples was 4 257
556.901 [ranging from 296 655 to 115 682 098].Human herpesvirus
Human herpesvirus (HHV) sequences were detected in
22 of 78 samples (6 OVHs and 16 OVCs) with viralloads ranging from 0.01 to 0.58 viral genomes per cell
(see Table III) and with 0.19 viral loads SD. There were
12 samples positive for HHV-1, 1 for HHV-4, 4 for
HHV-5, 5 for HHV-6B, 3 for HHV-6A, and 1 forHHV-7. Four cases had double HHV infections (HHV-
1 and -5, HHV-1 and -6A, HHV-1 and -6B, and HHV-
6A and -6B).
DISCUSSION
We have described the use of NGS as a validated,
powerful, high-throughput method to investigate the
presence of all characterized human viral genome loads
and subtypes, in the largest, speciﬁcally oral, verrucous
sample cohort described to date. Using NGS, testing for
all HPV subtypes found HPV-16 positivity in only 1
OVH and 1 OVC sample and HPV-2 positivity in 1
OVC sample out of 78 oral verrucous lesions with 2.2,
8.1, and 0.3 viral genomes per cell, respectively.
Although it is difﬁcult to accurately predict the exact
viral load with only a very small number of aligning
viral reads, loads in this study were much lower than
loads in our previous study of HNSCC.36 There the
standard deviation of the viral loads was 37.7, sug-
gesting that the virus was not contributing to disease
etiology. We have calculated the probability of detect-
ing a viral load of 1 HPV genome per cell, given our
read numbers. Of our 78 samples, 60 have sufﬁcient
depth to detect 1 HPV genome per cell. All but 4
samples have sufﬁcient depth to be able to detect 4
copies per cell with 95% conﬁdence.
HPV DNA may degrade in parafﬁn-embedded tis-
sues. Sequencing may be less affected by this than
PCR. The standard PCR test for HPV requires a 120-bp
fragment to be ampliﬁed. We size select our libraries to
be around 200 bp to ensure that enough fragments of
<100 bp are sequenced. If an HPV sequence is in one
of these, it would be picked up by sequencing but not
by PCR.
The recent article by Patel et al.24 used HPV reverse
transcription PCR (RT-PCR) testing, but they had a
signiﬁcant subset of cases in which insufﬁcient RNA
from the formalin-ﬁxed, parafﬁn-embedded tumor sec-
tions precluded HPV RT-PCR testing. Nevertheless,
they concluded that “active HPV in (head and neck)
verrucous carcinomas is rare enough to likely be clin-
ically inconsequential.”
In 2012, del Pino et al.23 investigated the prevalence
of HPV in 18 verrucous lesions. Using PCR, and
ﬁnding that only 1 head and neck VC was positive for
HPV infection, the authors concluded that VC is
Table III. Viral load determined by next generation sequencing in human oral verrucous carcinomas (n ¼ 62) and
hyperplasias (n ¼ 16)
Patient ID Species
Virus
length
Human
reads
Virus
reads
Read density
Kb per read
Kb virus
sequence
Viral
load
Detectable
HPV load at
95% conﬁdence
Probability of
detecting
1 copy of
HPV per cell
V-2-2-C1 Herpesvirus 5 235646 296655 1 20.23 20.23 0.09 7.6696 0.3233
V-2-2-C1 Herpesvirus 1 152261 296655 2 20.23 40.45 0.27 7.6696 0.3233
V-3-1-A1 - 0 431502 0 13.9 0 0 5.2728 0.4334
V-4-1-E9 - 0 589117 0 10.18 0 0 3.8621 0.5396
V-7-1-A Herpesvirus 6A 159322 671946 8 8.93 71.43 0.45 3.3860 0.5872
V-7-1-A Herpesvirus 1 152261 671946 1 8.93 8.93 0.06 3.3860 0.5872
V-8-1-C - 0 479578 0 12.51 0 0 4.7443 0.4682
V-10-1-1 - 0 1556862 0 3.85 0 0 1.4614 0.8712
V-14-1-6 - 0 1288201 0 4.66 0 0 1.7662 0.8166
V-15-A3 - 0 1554350 0 3.86 0 0 1.4638 0.8708
V-19-I4 - 0 1182923 0 5.07 0 0 1.9234 0.7893
V-20-3 - 0 4253014 0 1.41 0 0 0.5350 0.9963
V-22-1-4 HPV-16 7905 2368058 7 2.53 17.74 2.24 0.9608 0.9558
V-23-1-5 - 0 378361 0 15.86 0 0 6.0134 0.3924
V-25-1-D2 - 0 668260 0 8.98 0 0 3.4047 0.5852
V-26-1-A4 - 0 666770 0 8.99 0 0 3.4123 0.5844
V-29-2-A3 - 0 840256 0 7.14 0 0 2.7078 0.6692
V-30-1 Herpesvirus 1 152261 2943604 4 2.04 8.15 0.05 0.7729 0.9793
V-31-1-B1 - 0 583436 0 10.28 0 0 3.8997 0.5361
V-33-1-4 Herpesvirus 6A 159322 1182195 18 5.08 91.36 0.57 1.9246 0.7891
V-33-1-4 Herpesvirus 6B 162114 1182195 1 5.08 5.08 0.03 1.9246 0.7891
V-38-1-B - 0 9163412 0 0.66 0 0 0.2483 1.0000
V-40-1 - 0 7611248 0 0.79 0 0 0.2989 1.0000
V-41-1-G - 0 2324407 0 2.58 0 0 0.9788 0.9531
V-42-1-G Herpesvirus 1 152261 14884005 6 0.4 2.42 0.02 0.1529 1.0000
V-44-1-3J Herpesvirus 1 152261 4793286 2 1.25 2.5 0.016 0.4747 0.9982
V-46-1-2 Herpesvirus 6B 162114 12047262 150 0.5 74.71 0.46 0.1889 1.0000
V-60-1 - 0 289026 0 20.76 0 0 7.8721 0.3165
V-61-1-4 - 0 4901408 0 1.22 0 0 0.4642 0.9984
V-62-1-B Herpesvirus 6A 159322 5978774 2 1 2.01 0.13 0.3806 0.9996
V-63-1-2 - 0 6794116 0 0.88 0 0 0.3349 0.9999
V-65-1-D1 - 0 7769042 0 0.77 0 0 0.2929 1.0000
V-66-1-B - 0 4446770 0 1.35 0 0 0.5117 0.9971
V-67-1-B1 - 0 6100026 0 0.98 0 0 0.3730 0.9997
V-68-1 Herpesvirus 5 235646 2984540 4 2.01 8.04 0.03 0.7623 0.9803
V-69-1-D Herpesvirus 5 235646 8960354 2 0.67 1.34 0.01 0.2539 1.0000
V-70-1-B Herpesvirus 7 153080 6371664 2 0.94 1.88 0.01 0.3571 0.9998
V-71-1-5 - 0 7896410 0 0.76 0 0 0.2881 1.0000
V-72-1-4 - 0 6091470 0 0.99 0 0 0.3735 0.9997
V-73-1 - 0 7774162 0 0.77 0 0 0.2927 1.0000
V-74-1-A - 0 8256130 0 0.73 0 0 0.2756 1.0000
V-75-1 - 0 1527565 0 3.93 0 0 1.4895 0.8662
V-77-1 - 0 7883782 0 0.76 0 0 0.2886 1.0000
V-78-1-A Herpesvirus 5 235646 6029256 4 0.99 3.98 0.017 0.3774 0.9996
V-79-1-B Herpesvirus 6B 162114 6483082 2 0.93 1.85 0.01 0.3510 0.9998
V-80-1 - 0 3288128 0 1.83 0 0 0.6920 0.9868
V-83-1-C - 0 5666808 0 1.06 0 0 0.4015 0.9994
V-84-1 - 0 4969566 0 1.21 0 0 0.4578 0.9986
V-85-1 - 0 5348678 0 1.12 0 0 0.4254 0.9991
V-86-1 - 0 15107456 0 0.4 0 0 0.1506 1.0000
V-87-1 - 0 5178734 0 1.16 0 0 0.4393 0.9989
V-88-1 Herpesvirus 1 152261 6584298 2 0.91 1.82 0.01 0.3456 0.9998
V-89-1-A - 0 6898174 0 0.87 0 0 0.3298 0.9999
V-90-1 - 0 4493076 0 1.34 0 0 0.5064 0.9973
V-91-1 Herpesvirus 1 152261 8733136 2 0.69 1.37 0.01 0.2605 1.0000
V-92-1 Herpesvirus 1 152261 10556564 4 0.57 2.27 0.02 0.2155 1.0000
V-94-1 HPV-2 7860 4614998 2 1.3 2.6 0.33 0.4930 0.9977
(continued )
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Table III. Continued
Patient ID Species
Virus
length
Human
reads
Virus
reads
Read density
Kb per read
Kb virus
sequence
Viral
load
Detectable
HPV load at
95% conﬁdence
Probability of
detecting
1 copy of
HPV per cell
V-94-1 Herpesvirus 1 152261 4614998 4 1.3 5.2 0.03 0.4930 0.9977
V-95-1-B Herpesvirus 1 152261 11163878 4 0.54 2.15 0.01 0.2038 1.0000
V-95-1-B Herpesvirus 6B 162114 11163878 4 0.54 2.15 0.01 0.2038 1.0000
V-97-1 - 0 9483722 0 0.63 0 0 0.2399 1.0000
V-98-1-D - 0 7454606 0 0.81 0 0 0.3052 0.9999
V-99-1-4 - 0 6585616 0 0.91 0 0 0.3455 0.9998
V-100-1-B - 0 4716241 0 1.27 0 0 0.4824 0.9980
V-101-1-F - 0 4412444 0 1.36 0 0 0.5156 0.9970
V-102-1 - 0 6610388 0 0.91 0 0 0.3442 0.9998
V-104-01 Herpesvirus 1 152261 10385806 8 0.58 4.62 0.03 0.0114 1.0000
V-105-01 Herpesvirus 1 152261 10847800 2 0.55 1.10 0.01 0.0109 1.0000
V-106-01 - 0 9112970 0 0.66 0 0 0.2497 1.0000
V-108-01 - 0 13893548 0 0.43 0 0 0.1638 1.0000
V-109-T Herpesvirus 4 171823 14969258 6 0.40 2.41 0.01 0.006988318 1.0000
V-110-01 - 0 12720402 0 0.47 0 0 0.1789 1.0000
V-111-01 - 0 9047886 0 0.66 0 0 0.2515 1.0000
V-113-T - 0 4086390 0 1.47 0 0 0.5568 0.9954
V-114-T - 0 7797994 0 0.77 0 0 0.2918 1.0000
V-115-01 - 0 15682098 0 0.38 0 0 0.1451 1.0000
V-116-T - 0 10659704 0 0.56 0 0 0.2134 1.0000
V-118-01 - 0 15473750 0 0.39 0 0 0.1471 1.0000
V-120-T - 0 8762276 0 0.68 0 0 0.2597 1.0000
V-122-01 - 0 12558750 0 0.48 0 0 0.1812 1.0000
V-123-T - 0 11502764 0 0.52 0 0 0.1978 1.0000
V-124-T Herpesvirus 6B 162114 9115790 142 0.66 93.46 0.58 0.0122 1.0000
V-125-T HPV-16 7905 10041734 108 0.60 64.53 8.16 0.2264 1.0000
HPV, human papillomavirus.
OOOO ORIGINAL ARTICLE
Volume 118, Number 1 Samman et al. 123“unlikely to be related to HPV infection.” In addition,
Stokes et al.25 studied the role of HPV in malignant and
dysplastic oral verrucous lesions and suggested that
although high-risk HPV DNA was identiﬁed in 1 of 7
carcinomas and 5 of 13 dysplasias, the oncogenic pro-
cess is not enhanced by HPV oncoproteins, as p16
overexpression was lacking; they concluded that further
work is needed on a larger cohort to determine HPV’s
biologic signiﬁcance in VC development.
We have used NGS for the detection of HPV in
verrucous samples on the largest cohort of oral verru-
cous carcinomas to date. In addition, we used histologic
diagnostic criteria deﬁned by the World Health Orga-
nization,19 suggesting (unlike Patel et al.24) that oral
verrucous lesions with frank stromal invasion in the
bulk of the tumor should be classiﬁed as SCCs with
verrucous architecture and therefore should be excluded
from study.
Our method using NGS was validated previously (on
our control sample set) by detecting HPV sequences
using PCR and by evaluating p16 expression as a
marker for HPV infection.36 We found in our previous
study that NGS has a high speciﬁcity and sensitivity for
HPV detection when compared with PCR and p16. It
has been previously suggested that PCR methods canbe oversensitive,37 whereas our method can provide
better speciﬁcity, as demonstrated by our observation
that all p16-positive samples were also positive for
HPV-16 by sequencing.36 NGS has also been validated
for detecting papilloma subtypes and loads not identi-
ﬁed by other means in cervical samples.38
In this study, we searched for all human viruses with
sequenced genomes. HHV types were detected in one-
third of lesions, although they were unconﬁrmed using
any other diagnostic test. NGS tells us nothing about
transcriptional activity, so it is not possible to speculate
further on the clinical signiﬁcance of this ﬁnding. In
addition, we scanned the control samples used in our
previous study36 for all human virus sequences and
identiﬁed 8 positive cases (34.78%). In general, herpes
simplex viruserelated infections are common, affecting
approximately two-thirds of adults. Two HHV types
known to be associated with cancer, Kaposi sarcomae
associated herpesvirus and Epstein-Barr virus,39 were
not detected. Herpes infection may not be the cause of
the disease in our patients, but future studies of a similar
nature may reveal previously unsuspected oncoviruses
to be common in a different tumor type. The fact that
our read depth is enough to detect 1 HPV copy per cell
with 95% conﬁdence in most of our samples and a
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124 Samman et al. July 2014modest infection of 5 copies per cell in all but 5,
combined with our previous ease of detecting HPV in
oropharyngeal cancer, conﬁrms that the absence of
detection of HPV in this large sample is not a technical
error but a real biologic ﬁnding.
The authors thank Catherine Daly and Rebecca Chalkley for
providing technical training.
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APPENDIX
Supplemental Table S1. Next-generation sequencing
analysis for detecting human papillomavirus in oral
verrucous carcinoma
Patient ID Sex Age (y) Lesion location* Diagnosis
V-2-2-C1 F 60 Mandible and BM OVH
V-3-1-A1 F 62 Mandible and BM OVH
V-4-1-E9 M 77 Mandible and BM OVC
V-7-1-A F 86 Lower lip OVC
V-8-1-C F 38 FOM OVC
V-10-1-1 e1 M 62 BM OVC
V-14-1-6 M 62 BM OVC
V-15-1-A3 F 75 HP and BM OVH
V-19-1-I4 F 63 BM OVC
V-20-3 M 54 SP OVC
V-22-1-4 F 67 BM OVH
V-23-1-5 F 78 BM OVC
V-25-1-D2 F 80 Tongue OVH
V-026-01-A4 M 72 BM OVC
V-29-2-A3 F 52 HP OVH
V-30-1 F 80 BM OVH
V-31-1-B1 M 72 BM OVH
V-33-01-4 M 72 BM OVH
V-38-1-B M 63 BM OVC
V-40-1 F 63 Maxilla OVH
V-41-1-G M 67 Maxilla OVH
V-42-1-G F 70 Tongue OVH
V-44-1-3J M 54 Tongue OVH
V-46-1-2 M 60 HP OVH
V-60-1 M 65 Tongue OVC
V-61-1-4 F 96 Tongue OVC
V-62-1-B F 73 Tongue OVC
V-63-1-2 F 66 BM OVC
V-65-1-D1 M 78 Upper lip OVC
V-66-1-B M 73 BM OVC
V-67-1-B1 F 61 FOM OVC
V-68-1 M 61 BM OVC
V-69-1-D M 66 Lower lip and BM OVC
V-70-1-B M 49 BM OVC
V-71-1-5 F 82 Mandible OVC
V-72-1-4 F 82 BM OVC
V-73-1 F 88 Mandible OVC
V-74-1-A F 88 HP OVC
V-75-1 F 49 BM OVC
V-77-1 M 81 BM OVC
V-78-1-A M 74 BM OVC
V-79-1-B F 77 HP/SP OVC
V-80-1 F 63 Mandible OVC
V-83-1-C F 72 Mandible and BM OVC
V-84-1 F 61 BM OVC
V-85-1 M 73 BM OVC
V-86-1 M 70 Tongue OVC
V-87-1 F 53 BM OVC
V-88-1 M 74 BM OVC
V-89-1-A M 53 BM OVC
V-90-1 M 61 BM OVC
V-91-1 F 60 HP OVC
V-92-1 M 57 BM OVC
V-94-1 M 46 BM OVC
V-95-1-B M 53 BM OVH
V-98-1-D F 85 Tongue OVC
(continued )
Supplemental Table S1. Continued
Patient ID Sex Age (y) Lesion location* Diagnosis
V-99-1-4 F 81 Tongue OVC
V-100-1-B M 69 BM OVC
V-101-1-F F 80 SP OVC
V-102-1 F 55 BM OVC
V-104-01 F 78 Tongue OVC
V-105-01 M 47 Tongue OVC
V-106-01 F 76 Tongue OVH
V-108-01 F 78 Tongue OVC
V-109-T F 82 HP OVC
V-110-01 F 82 BM OVC
V-111-01 F 58 Lower lip OVC
V-112-T F 79 HP OVC
V-113-T M 64 Maxilla OVC
V-114-T M 53 Tongue OVC
V-115-01 M 43 Tongue OVC
V-116-T M 60 Hard palate/maxilla OVC
V-118-01 M 58 BM OVC
V-120-T F 45 BM OVC
V-122-01 M 76 FOM OVC
V-123-T M 60 Hard palate/maxilla OVC
V-124-T M 66 SP OVC
V-125-T M 64 Tongue OVC
BM, buccal mucosa; FOM, ﬂoor of mouth; HP, hard palate; SP, soft
palate; OVH, oral verrucous hyperplasia; OVC, oral verrucous
carcinoma.
*Mandible and maxilla refer to alveolus.
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